TME Pharma N.V. (0N6A.F)
| Previous Close | 0.2670 |
| Open | 0.2405 |
| Bid | 0.2630 x N/A |
| Ask | 0.2770 x N/A |
| Day's Range | 0.2405 - 0.2645 |
| 52 Week Range | 0.1774 - 1.7803 |
| Volume | |
| Avg. Volume | 3,389 |
| Market Cap | 7.56M |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
BERLIN, April 02, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma's CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma
Business WireTME Pharma Provides Results of First Exercise of Warrants Z
BERLIN, March 28, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the first exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 479,624 Warrants Z has resulted in the issuance of 599,530 new shares for gross proceeds
Business WireTME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer
BERLIN, March 05, 2024--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)1 application for NOX-A12, TME Pharma's CXCL12 inhibitor, for use in the treatment of aggressive adult brain cancer, glioblastoma.
